HDL CHOLESTEROL IS ASSOCIATED WITH PBMC EXPRESSION OF GENES INVOLVED IN HDL METABOLISM AND ATHEROGENESIS

POVEZANOST HDL HOLESTEROLA SA PBMC EKSPRESIJOM GENA KOJI SU UKLJUČENI U HDL METABOLIZAM I ATEROGENEZU

Liudmila V. Dergunova¹, Elena V. Nosova¹, Veronika G. Dmitrieva^{1,2}, Alexandra V. Rozhkova¹, Ekaterina V. Bazaeva², Svetlana A. Limborska¹, Alexander D. Dergunov²

¹Laboratory of Functional Genomics, Institute of Molecular Genetics of the Russian Academy of Sciences, Moscow, Russia

²Laboratory of Structural Fundamentals of Lipoprotein Metabolism, National Research Centre for Preventive Medicine, Moscow, Russia

Summary

Background: To reveal the association of plasma level of high density lipoprotein cholesterol (HDL-C) level with the transcript level of annotated genes in peripheral blood mononuclear cells (PBMC) and involved in HDL metabolism and atherogenesis at the absence of morphologically evident coronary stenosis.

Methods: Transcript levels of 63 genes in PBMC from 38 male patients 40–60 years without coronary atherosclerosis with widely varied HDL-C level were measured. The protein interactions were analyzed with STRING database.

Results: Among 22 HDL-related genes, the transcript levels for 10 genes (*ABCA1*, *BMP1*, *CUBN*, *HDLBP*, *LCAT*, *LDLR*, *PRKACB*, *PRKACG*, *SCARB1* and *ZDHHC8*) negatively correlated with HDL-C, while positively for *APOA1* gene. Among 41 atherosclerosis-prone genes, the transcript levels for 11 genes (*CSF1R*, *CSF2RB*, *IL18R1*, *ITGAM*, *ITGB3*, *PRKCK*, *SREBF1*, *TLR5*, *TLR8*, *TNFRSF1A* and *TNFRSF1B*) negatively correlated with HDL-C only, not with LDL-C and plasma TG. The protein products efficiently interacted within each cluster while only two intersection nodes existed between clusters.

Conclusions: Coordinate regulation of cholesterol influx and efflux in PBMC in atherosclerosis-free subjects with widely varied HDL-C level is suggested. The decreased synthesis and transport of cholesterol ester to the liver may

Kratak sadržaj

Uvod: Cilj rada je otkrivanje povezanosti nivoa lipoproteinskog holesterola visoke gustine u plazmi (HDL-C) sa nivoom transkripta anotiranih gena u mononuklearnim ćelijama periferne krvi (PBMC), a koji su uključeni u HDL metabolizam i aterogenezu u odsustvu morfološki evidentne koronarne stenoze.

Metode: Izmereni su nivoi transkripta 63 gena u PBMC kod 38 pacijenata muškog pola starosti između 40 i 60 godina bez koronarne ateroskleroze sa značajno raznovrsnim nivoom HDL-C. Interakcije proteina su analizirane pomoću STRING baze podataka.

Rezultati: Među 22 gena povezana sa HDL, nivoi transkripta za 10 gena (*ABCA1*, *BMP1*, *CUBN*, *HDLBP*, *LCAT*, *LDLR*, *PRKACB*, *PRKACG*, *SCARB1* i *ZDHHC8*) su bili u negativnoj korelaciji sa HDL-C, dok je korelacija pozitivna za gen *APOA1*. Od 41 gena koji su skloni aterosklerozi, nivoi transkripta za 11 gena (*CSF1R*, *CSF2RB*, *IL18R1*, *ITGAM*, *ITGB3*, *PRKCK*, *SREBF1*, *TLR5*, *TLR8*, *TNFRSF1A* i *TNFRSF1B*) su u negativnoj korelaciji samo sa HDL-C, ali ne sa LDL-C, i TG u plazmi. Proteinski proizvodi efikasno su delovali u svakom klasteru, dok su između klastera postojala samo dva čvora preseka.

Zaključak: Predlaže se koordinisana regulacija priliva i odliva holesterola u PBMC kod subjekata bez ateroskleroze sa širokim opsegom vrednosti nivoa HDL-C. Smanjena sinteza

Address for correspondence:

Liudmila V. Dergunova, PhD.
2, Kurchatov square, 123182 Moscow, Russia
Phone: +7 (499) 196-1858
e-mail: lvdergunova@mail.ru

List of abbreviations: Chol, cholesterol; FDR, false discovery rate; GWAS, genome wide association study; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PBMC, peripheral blood mononuclear cells; qPCR, quantitative polymerase chain reaction; RCT, reverse cholesterol transport; RT-PCR, real-time polymerase chain reaction; TG, triglyceride.

contribute to hyperalphalipoproteinemia. HDL-C increase is associated with the decrease of expression of innate immunity and inflammation genes. Visualization of 22 responder genes is suggested to be useful in the validation of HDL functionality and atherogenesis even at the absence of morphologically evident coronary stenosis.

Keywords: atherogenesis, gene expression, HDL functionality, HDL and atherogenesis-prone genes, human PBMC

Introduction

Coronary heart disease is one of the major mortality causes around the globe (1). The major underlying effects are the disturbances of lipid metabolism and atherogenesis with the contribution of immunological and metabolic processes (2). For a long time, the primary goal in the treatment of atherogenic dyslipidemia was to decrease the low-density lipoprotein cholesterol (LDL-C) and to increase high-density lipoprotein cholesterol (HDL-C). The proatherogenic role of LDL was opposed to the atheroprotective role of HDL as cholesterol acceptors (3), thus forming the reverse cholesterol transport (RCT) from lipid-loaded macrophages to the liver (4). Also, HDL possesses many pleiotropic atheroprotective properties such as endothelium protection, antioxidant, anti-inflammatory, anti-apoptotic and anti-thrombotic effects (5, 6). However, some genetic and clinical data challenged the atheroprotective significance of circulating HDL. The functional mutations of *ABCA1* gene with low HDL-C levels did not increase the risk of coronary heart disease (7), while the increase of HDL-C level did not decrease the risk (8) and even increased it in some circumstances. GWAS studies revealed many single nucleotide polymorphisms associated with HDL content without any definitive conclusions on the association of HDL-C with coronary heart disease (9). The loss of the atheroprotective properties of HDL may be related to their functional properties, not with their concentration (10). The appearance of dysfunctional HDL may be caused by the loss of anti-inflammatory and antioxidant proteins with the concomitant appearance of pro-inflammatory proteins in HDL particles (11, 12). Thus, the epidemiology, genetics, clinical and experimental data accumulated up to date do not unequivocally relate HDL-C as an anti-atherogenic factor.

To reveal the HDL role on the transcriptome level, we selected some genes with the expression in peripheral blood mononuclear cells (PBMC) (13). Among them, 22 genes involved in HDL metabolism (HDL cluster) were chosen. In addition, 41 genes involved in inflammation and other atherogenesis-prone processes (atherogene cluster) were included based on the GWAS data on differentially expressed genes in PBMC in atherosclerosis versus control and RT-PCR data (13). In a pilot study with a small group of patients without coronary atherosclerosis, we com-

pared the expression of HDL cluster genes in PBMC, HDL charge heterogeneity and cholesterol acceptor capacity of patient HDL in cholesterol efflux assay (14). The expression of several HDL-related genes, cholesterol efflux efficiency and concentration of pre β -HDL significantly differed between hypo- and hyperalphalipoproteinemics (14). However, the joint consideration of the expression of atheroprotective and pro-atherogenic genes in relation to HDL-C level in the same group of patients is still lacking.

Ključne reči: aterogeneza, ekspresija gena, HDL funkcionalnost, HDL i geni skloni aterogenezi, humani PBMC

pared the expression of HDL cluster genes in PBMC, HDL charge heterogeneity and cholesterol acceptor capacity of patient HDL in cholesterol efflux assay (14). The expression of several HDL-related genes, cholesterol efflux efficiency and concentration of pre β -HDL significantly differed between hypo- and hyperalphalipoproteinemics (14). However, the joint consideration of the expression of atheroprotective and pro-atherogenic genes in relation to HDL-C level in the same group of patients is still lacking.

The aim of the present study is to reveal the association of plasma level of high-density lipoprotein cholesterol level with the transcript level of selected genes in peripheral blood mononuclear cells (PBMC) and involved in HDL metabolism and atherogenesis at the absence of morphologically evident coronary stenosis.

Materials and Methods

Patients and laboratory tests

Thirty-eight white Caucasian male patients at the age between 40 and 60 from the Moscow region were enrolled in the study (Table I). The inclusion criteria were the absence of coronary deficiency and stenosis of coronary/carotid arteries verified by coronary angiography and ultrasonography, respectively, the absence of hypertension and diabetes, non-alcoholics, the absence of therapy by corticosteroids and

Table I Characteristics of the study group. White Caucasian male patients from the Moscow region were enrolled in the study. Parameter variations between minimal and maximal values are given also.

	Mean $\pm$ SD (n = 38)	Variation
Age, years	49.1 $\pm$ 5.7	40.0 – 60.0
Body mass index, kg/m ²	28.5 $\pm$ 3.1	21.0 – 31.0
Chol, mmol/L	5.19 $\pm$ 1.27	2.40 – 7.80
HDL-C, mmol/L	1.19 $\pm$ 0.35	0.59 – 2.24
LDL-C, mmol/L	3.31 $\pm$ 1.05	1.14 – 5.98
TG, mmol/L	1.52 $\pm$ 0.71	0.59 – 3.42

hypolipidemic agents for at least 3 months. The informed consent was obtained from each patient, and the local ethical committee approved protocol corresponding to the Helsinki declaration from 1975. Plasma lipid levels (*Table I*) were measured by enzyme methods with Architect c8000 (Abbott, USA).

Gene expression analysis by quantitative real-time PCR

Ficoll-Hypaque (1.077 g/mL) density gradient centrifugation (Sigma, USA) was performed to isolate peripheral blood mononuclear cells. Total RNA was isolated with TRI Reagent (Molecular Research Center, USA) and traces of DNA were removed by DNase I in the presence of RNase inhibitor according to the manufacturer's protocol (ThermoFisher Scientific, USA). RNA samples were kept at -70 °C. RNA concentration and quality (RQI > 9) were measured with the Experion electrophoresis system (Bio-Rad, USA). cDNA was synthesized with RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific, USA) and cDNA samples were kept at -20 °C.

HDL cluster included the following genes: Albumin (*ALB*); Alpha-2-macroglobulin (*A2M*); Amnion associated transmembrane protein (*AMN*); Apolipoprotein A1 (*APOA1*); Apolipoprotein C2 (*APOC2*); Apolipoprotein E (*APOE*); ATP binding cassette subfamily A member 1 (*ABCA1*); ATP binding cassette subfamily G member 1 (*ABCG1*); Bone morphogenetic protein 1 (*BMP1*); Cholesteryl ester transfer protein (*CETP*); Cubilin (*CUBN*); High density lipoprotein binding protein (*HDLBP*); Lecithin-cholesterol acyltransferase (*LCAT*); Lipase C, hepatic type (*LIPC*); Lipoprotein lipase (*LPL*); Low density lipoprotein receptor (*LDLR*); Phospholipid transfer protein (*PLTP*); Protein kinase cAMP-activated catalytic subunit alpha (*PRKACA*); Protein kinase cAMP-activated catalytic subunit beta (*PRKACB*); Protein kinase cAMP-activated catalytic subunit gamma (*PRKACG*); Scavenger receptor class B member 1 (*SCARB1*); Zinc finger DHHC-type containing 8 (*ZDHHC8*).

Atherogene cluster included the following genes: Asialoglycoprotein receptor 2 (*ASGR2*); CD14 molecule (*CD14*); CD36 molecule (*CD36*); Coagulation factor V (*F5*); Colony stimulating factor 1 receptor (*CSF1R*); Colony stimulating factor 2 receptor beta common subunit (*CSF2RB*); C-X-C motif chemokine ligand 5 (*CXCL5*); Cytochrome b-245 alpha chain (*CYBA*); Integrin subunit alpha 2b (*ITGA2B*); Integrin subunit alpha M (*ITGAM*); Integrin subunit beta 3 (*ITGB3*); Intercellular adhesion molecule 1 (*ICAM1*); Interleukin 1 beta (*IL1B*); Interleukin 1 receptor type 1 (*IL1R1*); Interleukin 18 (*IL18*); Interleukin 18 receptor 1 (*IL18R1*); Interleukin 18 receptor accessory protein (*IL18RAP*); Junctional adhesion molecule 3 (*JAM3*); Lymphotoxin

alpha (*LTA*); Matrix metalloproteinase 9 (*MMP9*); Microsomal glutathione S-transferase 1 (*MGST1*); NPC intracellular cholesterol transporter 1 (*NPC1*); NPC intracellular cholesterol transporter 2 (*NPC2*); Nuclear receptor subfamily 1 group H member 2 (*NR1H2*); Nuclear receptor subfamily 1 group H member 3 (*NR1H3*); Oxidized low density lipoprotein receptor 1 (*OLR1*); Phosphatidylcholine transfer protein (*PCTP*); Phospholipase A2 group VII (*PLA2G7*); Protein kinase C theta (*PRKCQ*); S100 calcium binding protein A12 (*S100A12*); S100 calcium binding protein A8 (*S100A8*); S100 calcium binding protein A9 (*S100A9*); Secretory leukocyte peptidase inhibitor (*SLPI*); Solute carrier family 7 member 11 (*SLC7A11*); Sterol regulatory element binding transcription factor 1 (*SREBF1*); Superoxide dismutase 2 (*SOD2*); TNF receptor superfamily member 1A (*TNFRSF1A*); TNF receptor superfamily member 1B (*TNFRSF1B*); Toll like receptor 5 (*TLR5*); Toll like receptor 8 (*TLR8*); Vascular endothelial growth factor A (*VEGFA*).

Housekeeping genes included Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*); Lactate dehydrogenase A (*LDHA*) and Ribosomal protein L3 (*RPL3*) genes.

Gene-specific primers were designed using OLIGO Primer Analysis Software 6.31 (Molecular Biology Insights, USA). Primer structures and coordinates according to mRNA for forty-one genes involved in atherogenesis and for two HDL-related *LDLR* and *LIPC* genes are given in *Table II*. We described earlier the primers for three housekeeping *GAPDH*, *RPL3* and *LDHA* genes and for twenty HDL-related genes *ABCA1*, *ABCG1*, *SCARB1*, *CETP*, *PRKACA*, *PRKACB*, *PRKACG*, *LCAT*, *HDLBP*, *ZDHHC8*, *A2M*, *AMN*, *ALB*, *CUBN*, *BMP1*, *LPL*, *PLTP*, *APOA1*, *APOE* and *APOC2* (14). Analysis of primer specificity and protocol of real-time quantitative polymerase chain reaction (qPCR) were performed as previously described (14).

Analysis of interaction between protein products of genes belonging to two clusters

The analysis was performed with STRING database (15) with six kmeans clusters. The *p*-value for protein-protein interaction (PPI) enrichment is an indicator of interaction efficiency. The number of nodes and the number of edges are network characteristics.

Statistical analysis

Statistical analysis was performed using STATISTICA 8.0 data analysis software system (StatSoft, Inc. (2008)). We applied the Shapiro-Wilks *W* test to check the normality and nonnormally distributed data were log-transformed to approach a Gaussian distribution. The data are expressed as mean ± SD. The

Table II The primers used for a quantitative real-time polymerase chain reaction.

Primer	GeneBank	5'- 3' nucleotide sequence	location	efficiency
Genes involved in atherogenesis				
ASGR2 (F)	NM_001181.4	GGAGAAACAGCAGCAGGACC	663–682	1.65
ASGR2 (R)		GAGTGAGAGAACCAGTAGCAGC	827–848	
CD14 (F)	NM_000591.3	CAAGTGTGAAGCCTGGAAGC	277–296	1.80
CD14 (R)		ACAAGGTTCTGGCGTGGTC	436–454	
CD36 (F)	NM_000072.3	CCTTTGCCTCTCCAGTTGAA	1310–1329	1.99
CD36 (R)		GTACACAGGTCTCCCTTCTTTG	1413–1434	
CSF1R (F)	NM_005211.3	GGTGGCAGGAAGGTGATGT	836–854	1.71
CSF1R (R)		GGTGTTGTTGTGTTGGAGGA	999–1018	
CSF2RB (F)	NM_000395.2	ATCCTCCTCTCCAACACCTCC	776–796	1.80
CSF2RB (R)		ACCTCCTTCCTCACCTCCCA	1001–1020	
CXCL5 (F)	NM_002994.4	GCTGTTGGTGCTGCTGCT	208–225	1.81
CXCL5 (R)		CCGTTCTTCAGGGAGGCTAC	389–408	
CYBA (F)	NM_000101.3	TTGTGTGCCTGCTGGAGTA	214–232	1.70
CYBA (R)		AGTAGGTAGATGCCGCTCG	421–439	
F5 (F)	NM_000130.4	CTGGCTGGTGGCTCCTAA	5781–5798	1.57
F5 (R)		ATCTTGCTAATCTGGGCTCC	5941–5960	
JAM3 (F)	NM_032801.4	TTCCAGAGCCAATCCCAGA	708–726	1.90
JAM3 (R)		TCCGCCAATGTTTCAGGTC	874–891	
ICAM1 (F)	NM_000201.2	GTGACCGTGAATGTGCTCTCC	1727–1747	1.83
ICAM1 (R)		GAGGCGTGGCTTGTGTGTT	1895–1913	
IL1B (F)	NM_000576.2	TGTCCTGCGTGTTGAAAGATGA	641–662	1.84
IL1B (R)		CTGCTTGAGAGGTGCTGATGTA	796–817	
IL1R1 (F)	NM_000877.3	TGCTTACTGGAAGTGAATG	1099–1118	1.76
IL1R1 (R)		TGCTGCATCTATACCATGTG	1278–1297	
IL18 (F)	NM_001562.3	GACCAAGGAAATCGGCCT	395–412	1.81
IL18 (R)		CACAGAGATAGTTACAGCCATACC	503–526	
IL18RAP (F)	NM_003853.3	ACAACCCAGTCCGTC AAC	1524–1542	1.86
IL18RAP (R)		ACATCAGGAAATAGGCTCAGG	1790–1810	
IL18R1 (F)	NM_003855.3	CGATAAAGAAGAACGCCGAGT	655–675	1.68
IL18R1 (R)		GCAGAGCAGTTGAGCCTTACG	842–862	
ITGAM (F)	NM_001145808.1	CTCTCTCCCAGGCTCCAGT	1827–1845	1.79
ITGAM (R)		CATTCTTGCCACTTCCCT	1986–2004	
ITGA2B (F)	NM_000419.4	AAGATTGTGCTGCTGGACG	2421–2439	1.81
ITGA2B (R)		GAAGGTGGATGCTGAGGTGA	2612–2631	
ITGB3 (F)	NM_000212.2	AGTAACCTGCGGATTGGCTT	537–556	1.81
ITGB3 (R)		CACACTCTGCTTCTTCACTTCC	713–734	
LTA (F)	NM_001159740.2	GCTGCTGCTGGTTCTGCT	282–299	1.65
LTA (R)		GTTCTGCTTGCTGGGGTCT	420–438	
MGST1 (F)	NM_145792.2	CAGGTAATGGATGATGAAGTA	81–101	1.79
MGST1 (R)		GCCAAATGCTACACAGTCTTCT	206–227	
MMP9 (F)	NM_004994.2	ACCCTTGTGCTCTTCCCTG	98–116	1.70
MMP9 (R)		CGACTCTCCACGCATCTCTG	192–211	
NPC1 (F)	NM_000271.4	CAGCCACATAACCAGAGCGT	3778–3797	1.78
NPC1 (R)		AGCCAACACCACAATCCCT	3898–3916	

Table II continued				
NPC2 (F)	NM_006432.3	TCCCATTCTGAGCCTGAT	362–380	1.82
NPC2 (R)		GTTGCCACTCCACCACCA	478–495	
NR1H2 (F)	NM_007121.5	GCCATCATCTCAGTCCAGG	1104–1122	1.79
NR1H2 (R)		ACTCTGTCTCGTGGTTGTAGC	1237–1257	
NR1H3 (F)	NM_005693.3	GCCTTGCTCATTGCTATCAG	1319–1338	1.86
NR1H3 (R)		GTGGGAACATCAGTCGGTCA	1447–1466	
OLR1 (F)	NM_002543.3	TTGCCTGGGATTAGTAGTGACC	249–270	1.77
OLR1 (R)		CTTCTTCTGCTTGTTGCCG	376–394	
PCTP (F)	NM_021213.3	GGTGAAGCAATACAAGCAGAG	578–598	2.18
PCTP (R)		TAATGAGCCAGGACGGAAT	672–690	
PLA2G7 (F)	NM_005084.3	GGCATTGACCTGGCATCTC	759–777	1.86
PLA2G7 (R)		TGTGTCTCCTCCTCTTGTTTCAG	894–916	
PRKCQ (F)	NM_006257.4	ACTGCCACCTTCTTCCCAC	587–605	1.55
PRKCQ (R)		CTTGAGTCCTTGCCGTGC	866–883	
SLC7A11 (F)	NM_014331.3	GTCCGCAAGCACACTCCT	1358–1375	1.97
SLC7A11 (R)		ATGACGAAGCCAATCCCTG	1629–1647	
SLPI (F)	NM_003064.3	CCTTCCTGGTGCTGCTTG	44–61	2.28
SLPI (R)		GACAACATCTCTTCTTCCCTGG	193–214	
SOD2 (F)	NM_000636.3	CACCACAGCAAGCACCAC	309–326	1.80
SOD2 (R)		GTTCTCCACCACCGTTAGG	480–498	
SREBF1 (F)	NM_001005291.2	CCTCAGATACCACCAGCGTC	1828–1847	1.68
SREBF1 (R)		TTGCGATGCCTCCAGAAGT	2026–2044	
S100A8 (F)	NM_001319196.1	ATGCCGTCTACAGGGATGA	267–285	1.74
S100A8 (R)		ACGCCCATCTTTATCACCAG	407–426	
S100A9 (F)	NM_002965.3	GACCATCATCAACACCTTCCAC	82–103	1.68
S100A9 (R)		TAGCCTCGCCATCAGCAT	284–301	
S100A12 (F)	NM_005621.1	ATTAGGCTGGGAAGATGACAA	55–75	1.90
S100A12 (R)		GTGGGTGTGGTAATGGGCA	320–338	
TLR5 (F)	NM_003268.5	GACCCTCTGCCCCTAGAATAA	581–601	1.75
TLR5 (R)		GCCATCAAAGGAGCAGGAA	707–725	
TLR8 (F)	NM_016610.3	GGAACATCAGCAAGACCCATC	115–135	1.80
TLR8 (R)		CGCATAACTCACAGGAACCAGA	279–300	
TNFRSF1A (F)	NM_001065.3	GCTCCTTCACCGCTTCAGA	563–581	1.74
TNFRSF1A (R)		GGTCCCATTGAGGCAGAGG	744–762	
TNFRSF1B (F)	NM_001066.2	AACACACGCAGCCAACTCC	763–781	1.77
TNFRSF1B (R)		GTCACACCCACAATCAGTCCA	875–895	
VEGFA (F)	NM_001025366.2	GAGGGCAGAATCATCACGAA	1136–1155	1.79
VEGFA (R)		CATCAGGGGCACACAGGA	1264 – 1281	
HDL-related genes ^{*)}				
LDLR (F)	NM_000527.4	GAGGTGGCCAGCAATAGAA	1490–1508	2.00
LDLR (R)		GATGACGGTGTATAGGAAGAG	1572–1593	
LIPC (F)	NM_000236.2	CTTCAACTCCTCCCTGCCTCT	285–305	1.87
LIPC (R)		TGGTGTAGTGGTCGTGGGC	433–451	

^{*)} the data for other twenty HDL-related and three housekeeping genes were published (14).

analysis of primer efficiencies was done with the REST software (16), and the relative expression of all target genes normalized by the geometric mean of three reference genes was used in the correlation analysis. We did linear regression and Pearson's correlation r tests between biochemical variables with transcript levels to determine the statistical significance and correlation. We used the Benjamini-Hochberg correction for multiple comparisons with the false discovery rate (FDR) value as 0.15 within the recommended range of 0.10 - 0.20 (17). P -values < 0.05 were considered statistically significant.

Results

Expression of genes related to HDL metabolism

PBMC expression level of 22 genes included in HDL cluster was measured by RT-PCR and significant

associations of transcripts with plasma lipids are given in *Table III*. Significant associations existed between the transcripts of eleven genes and HDL-C. HDL-C level positively correlated with mRNA content of *APOA1* gene, while negatively with transcripts of cholesterol transporters (*ABCA1* and *SCARB1*), LDL receptor (*LDLR*), lecithin:cholesterol acyltransferase (*LCAT*), zinc finger DHHC-type containing 8 (*ZDHHC8*), bone morphogenetic protein 1 (*BMP1*), high density lipoprotein binding protein (*HDLBP*), cubilin (*CUBN*), protein kinase cAMP-activated catalytic subunit beta and gamma (*PRKACB*, *PRKACG*). Total cholesterol level also negatively correlated with transcript levels of the majority of the above-mentioned genes with the exception of *LDLR* and *PRKACB* genes. However, LDL-C level negatively correlated with transcripts of *CUBN* and *HDLBP* genes. Importantly, plasma TG level did not correlate with the transcript levels of HDL cluster genes.

Table III Bivariate correlations between transcript level of HDL cluster and atherogene cluster genes and lipids. Pearson correlation coefficient and p -values in brackets are included only for significant associations corrected for multiple comparisons by the Benjamini-Hochberg procedure. The functionality of protein products derived from STRING database and literature data is included also.

Gene	HDL-C	Chol	LDL-C	Protein functionality
<i>HDL cluster</i>				
<i>ABCA1</i>	-0.3759 (0.0200)	-0.3906 (0.0150)		cAMP-dependent and sulfonylurea-sensitive anion transporter. Key gatekeeper influencing intracellular cholesterol transport; Belongs to the ABC transporter superfamily. Activated by phosphorylation ATP-binding cassette transporter A1 (<i>ABCA1</i>) interacts with ApoA-I, allowing their lipidation and formation of pre- β HDL particles that leads to the efflux of free cholesterol and phospholipid from different cell types (18, 19).
<i>APOA1</i>	0.3579 (0.0270)			Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (<i>LCAT</i>). ApoA-I, a mature protein product of <i>APOA1</i> , as a part of pre- β HDL particles binds cellular cholesterol and phospholipids that leads to lipid efflux from the cell (20, 21).
<i>BMP1</i>	-0.4853 (0.0020)	-0.3654 (0.0240)		Cleaves the C-terminal propeptides of procollagen I, II and III. Induces cartilage and bone formation. May participate in dorsoventral patterning during early development by cleaving chordin (<i>CHRD</i>). Responsible for the proteolytic activation of lysyl oxidase <i>LOX</i> . Being the metalloproteinase, <i>BMP-1</i> leaves human 249-aa proapolipoprotein ApoA-I to generate the mature 243 aa polypeptide and leads to its activation for lipid binding and efflux from the cell as nascent HDL (22). This conversion is going in the presence of the cell surface lipid transporter <i>ABCA1</i> .
<i>CUBN</i>	-0.4282 (0.0070)	-0.4281 (0.0070)	-0.4360 (0.0060)	Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, <i>SCGB1A1</i> , <i>APOA1</i> , high-density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands requires calcium. The multi-ligand endocytic receptor Cubilin (<i>CUBN</i>), together with its coreceptor, LDL-related protein-2 (<i>LRP2</i>), can bind to apolipoprotein ApoA-I, a major component of HDL, and promote their endocytosis, which leads to their reabsorption into the plasma from glomerular filtrate, ensuring the maintenance of their plasma levels (23–25).

Table III continued

<i>HDLBP</i>	-0.3540 (0.0320)	-0.4733 (0.0030)	-0.4321 (0.0080)	Vigilin; Appears to play a role in cell sterol metabolism. It may function to protect cells from over-accumulation of cholesterol. The actual function of vigilin (<i>HDLBP</i>) is unknown. Vigilin induced by cholesterol and sterol hormones and found human atherosclerotic lesions. The high constitutive levels of vigilin mRNA in fibroblasts of patients with familial HDL deficiency may reflect impaired cholesterol transport in these cells (26, 27).
<i>LCAT</i>	-0.3536 (0.0290)	-0.3249 (0.0470)		Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low-density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Lecithin: cholesterol acyltransferase (<i>LCAT</i>) promotes the conversion of the discoidal (nascent) HDL to spherical HDL (28,29). <i>LCAT</i> reacts with the unesterified cholesterol in HDL, transferring the 2-acyl group of lecithin or phosphatidylethanolamine to the free hydroxyl residue of cholesterol to generate cholesteryl esters, which are retained in the core of HDL.
<i>LDLR</i>	-0.3784 (0.0230)			Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. The low-density lipoprotein receptor (<i>LDLR</i>) binds cholesterol-rich LDL particles and promote their clearance from the circulation into the cells where in the lysosomes cholesterol of LDL particles becomes available again by hydrolysis of the cholesteryl esters (30).
<i>PRKACB</i>	-0.3162 (0.0530)	-0.3637 (0.0270)		Mediates cAMP-dependent signalling triggered by receptor binding to GPCRs. PKA activation regulates diverse cellular processes such as cell proliferation, the cell cycle, differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion flux. Being the catalytic subunit of cAMP-dependent protein kinase (PKA), the protein product of <i>PRKACB</i> is involved in PKA-mediated ABCA1 phosphorylation, allowing lipidation of ApoA-I which leads to lipid efflux from the cell as nascent HDL (18, 31, 32).
<i>PRKACG</i>	-0.3569 (0.0300)	-0.4656 (0.0030)		Phosphorylates a large number of substrates in the cytoplasm and the nucleus; Belongs to the protein kinase superfamily. Being the catalytic subunit of cAMP-dependent protein kinase (PKA), the protein product of <i>PRKACG</i> is involved in PKA-mediated ABCA1 phosphorylation, allowing lipidation of ApoA-I which leads to lipid efflux from the cell as nascent HDL (18, 31, 32).
<i>SCARB1</i>	-0.4439 (0.0050)	-0.3655 (0.0240)		Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells. Receptor for HDL, mediating selective uptake of cholesteryl ether and HDL-dependent cholesterol efflux. Also facilitates the flux of free and esterified cholesterol between the cell surface and apoB-containing lipoproteins and modified lipoproteins, although less efficiently than HDL. Scavenger receptor class B type I (<i>SCARB1</i>) interacts with spherical and discoidal HDL particles and remodels the HDL (28).
<i>ZDHHC8</i>	-0.4923 (0.0020)			Palmitoyltransferase involved in glutamatergic transmission. Mediates palmitoylation of ABCA1. Palmitoylation of ABCA1 may regulate its function as a transporter and therefore lipid efflux from the cell (33).

Table III continued				
atherogene cluster				
CSF1R	-0.3512 (0.0330)			Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes.
IL18R1	-0.3898 (0.0170)			Within the IL18 receptor complex, responsible for the binding of the proinflammatory cytokine IL18, but not IL1A nor IL1B (Probable). Contributes to IL18-induced cytokine production, either independently of SLC12A3, or as a complex with SLC12A3.
ITGB3	-0.5355 (0.0010)			Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain.
ITGAM	-0.4039 (0.0130)			Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1.
SREBF1	-0.3666 (0.0260)			Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By similarity). Binds to the sterol regulatory element 1 (SRE-1) (5'-ATCACCCAC-3').
TLR5	-0.3649 (0.0240)			Participates in the innate immune response to microbial agents. Mediates detection of bacterial flagellins. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
TLR8	-0.5129 (0.0010)			Key component of innate and adaptive immunity. TLRs control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
TNFRSF1A	-0.3718 (0.0220)			Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signalling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.

Table III continued				
TNFRSF1B	-0.4677 (0.0030)			Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.
CSF2RB	-0.4080 (0.0120)			High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.
PRKCQ	-0.4077 (0.0140)			Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non- redundant functions in T-cell receptor (TCR) signalling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2.

Figure 1 STRING analysis of protein-protein interactions between proteins coded by genes from HDL and atherogene clusters. Six kmeans clusters are chosen. Number of nodes: 22; number of edges: 50; average node degree: 4.55; avg. local clustering coefficient: 0.647; expected number of edges: 11; PPI enrichment p-value: < 1.0e-16.

Expression of atherogenesis-prone genes

HDL-C negatively correlated with the transcript levels of eleven genes among 41 genes included in atherogene cluster (Table III). These genes code integrin subunit beta 3 (*ITGB3*), Toll-like receptors 5 and 8 (*TLR5* and *TLR8*), TNF receptor superfamily member 1A and 1B (*TNFRSF1A* and *TNFRSF1B*); interleukin 18 receptor 1 (*IL18R1*), integrin subunit alpha M (*ITGAM*); colony-stimulating factor 2 receptor beta common subunit (*CSF2RB*), colony-stimulating factor 1 receptor (*CSF1R*), sterol regulatory element-binding transcription factor 1 (*SREBF1*), and protein kinase C theta (*PRKCQ*).

Functional interactions between protein products of genes included in two clusters

The functional interactions between protein products of 22 genes, with PBMC expression level significantly associated with HDL-C level, were revealed by STRING database (15). The functional properties of proteins are included in Table III. Twenty-two nodes are involved in 50 interactions (Figure 1), which significantly exceeds eleven random interactions. Generally, nine from eleven genes from HDL cluster belong to Reactome Plasma lipoprotein assembly, remodelling, and clearance pathway (HSA-174824), based on minimal FDR value mentioned in STRING database. However, nine from eleven genes from the atherogene cluster belong to the Immune System pathway (HSA-168256). Two clusters intersect only at two nodes, namely *CSFR1* (six edges) and *CSF2RB* (two edges) (Figure 1).

Discussion

The associations between plasma lipids and PBMC expression of 63 genes included in two clusters were studied for a cohort of 38 middle-aged male patients without coronary atherosclerosis with widely varied HDL-C. For the first time, the significant positive correlation between HDL-C and *APOA1* expression and negative correlations of HDL-C and transcripts of ten HDL-related genes and eleven atherogenesis-prone genes even at the absence of morphologically evident coronary stenosis were revealed. The protein products efficiently interacted within both clusters, but only two-node intersections existed between them.

Monocytes are the main source of proinflammatory mediators at atherogenesis (34) that constitute one-fifth of the mononuclear cell fraction. PBMC expression of 41 genes included in the atherogene cluster was measured in the present study for 38 patients with a widely varied HDL-C level. HDL-C level negatively correlated with transcript content for eleven genes. The protein products of the some genes are of primary importance in inflammation and

immune response, namely colony-stimulating factor receptors, TNF receptor superfamily members 1A and 1B, TLR5 and TLR8 receptors that induce the proinflammatory cytokine, and IL18 cytokine receptor that participates in innate immunity response and is a critical molecule in atherosclerosis-connected inflammation (35). Molecular mechanisms of the inhibition of expression by HDL remain unknown. HDL inhibits endothelial and monocyte expression of tissue factor (TF), the major coagulation factor, by inhibiting the activation of p38 MAPK (mitogen-activated protein kinase) and the repression of the PI3K (phosphoinositide 3-kinase) pathway responsible for TF expression (36). It should be noted that the negative correlation between HDL-C and *ITGB3* and *ITGAM* gene transcripts observed here coincides with the inhibition of integrin and endothelial cell adhesion molecules by HDL (6, 37). Overall, our data on the negative correlation between HDL-C and pro-inflammatory gene transcripts suggest the decay of atherogenesis-related inflammation with the increase of HDL-C. Besides, PBMC expression of atherogenesis-sensitive genes is suggested to be controlled only by HDL-C level, due to the lack of any association with LDL-C and plasma TG. Both conclusions are the major novelties of our study.

The limitation of our study is the expression profiling of only two gene clusters; the genome-wide transcriptome analysis may reveal some additional genes involved in atherogenesis-related pathways. Also, a detailed study of mRNA and protein expression and enzyme and receptor activities would confirm the metabolic traits suggested to be influenced by the genes in two clusters. However, both mRNA and protein expression of HDLBP/vigilin is upregulated similarly by intracellular cholesterol loading (27).

The positive correlation between HDL-C and *APOA1* transcript existed among 22 HDL-related genes, while ten gene transcripts (*ABCA1*, *BMP1*, *CUBN*, *HDLBP*, *LCAT*, *LDLR*, *PRKACB*, *PRKACG*, *SCARB1* and *ZDHHC8*) correlated negatively; they included six genes mentioned earlier (14). Four gene transcripts (*CUBN*, *HDLBP*, *PRKACB*, and *PRKACG*) negatively correlated with HDL-C in the present study. The significant decrease of *HDLBP* which expression is upregulated by intracellular cholesterol loading (27), thus confirms our earlier suggestion (14) on the decreased level of cholesterol in PBMC at hyperalphalipoproteinemia. Additionally, the decrease of the *CUBN* transcript, which codes the receptor for apoA-I and HDL (25), may result in an increase of HDL level. A decrease in the content of *LCAT* and *SCARB1* transcripts may be suggested to result in the diminished flow of cholesteryl ester to the liver, thus contributing to hyperalphalipoproteinemia (14).

Functional relations between protein products of genes in two clusters include only two crossing genes. The existence of only two nodes may correspond to

the limited number of synchronous changes in node activities in both clusters and the possibility of discordant changes of cluster functionality. Functional isolation of two clusters may underlie the possibility of non-coincident changes between the loss of HDL function and the gain of dysfunction (12). Multiple pleiotropic effects, namely anti-inflammatory activity, vasodilatory function, antiapoptotic activity, antioxidative activity and cholesterol efflux capacity (12), characterize HDL functions. It may be speculated further that therapy targeting these two nodes, for instance by drugs and/or microRNA, may influence both HDL functionality and atherogenesis. Interestingly, one of two nodes, namely *CSF2RB* mRNA, possesses the greatest pleiotropy across six cardiometabolic traits (38).

Conclusion

Coordinate regulation of cholesterol influx and efflux in PBMC in atherosclerosis-free subjects with

widely varied HDL-C level is suggested. The decreased synthesis and transport of cholesteryl ester to the liver may contribute to hyperalphalipoproteinemia. HDL-C increase is associated with the decrease of expression of innate immunity and inflammation genes. Visualization of twenty-two responder genes is suggested to be useful in the validation of HDL functionality and atherogenesis even at the absence of morphologically evident coronary stenosis.

Acknowledgements. The reported study was funded by the Russian Foundation for Basic Research according to the research project No. 17-04-00217.

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol* 2017; 70: 1–25.
- Pirillo A, Bonacina F, Norata GD, Catapano AL. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. *Curr Atheroscler Rep* 2018; 20: 12.
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. *N Engl J Med* 2007; 357: 1301–10.
- Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al. HDL cholesterol efflux capacity and incident cardiovascular events. *N Engl J Med* 2014; 371: 2383–93.
- Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. *Curr Pharm Des* 2010; 16: 1480–93.
- Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. *Arterioscler Thromb Vasc Biol* 1995; 15: 1987–94.
- Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P et al. Association of loss-of-function mutations in the *ABCA1* gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA* 2008; 299: 2524–32.
- Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? *J Lipid Res* 2010; 51: 2058–73.
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 2010; 466: 707–13.
- Kosmas CE, Christodoulidis G, Cheng JW, Vittorio TJ, Lerakis S. High-density lipoprotein functionality in coronary artery disease. *Am J Med Sci* 2014; 347: 504–8.
- Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. *Drugs Context* 2018; 7: 212525.
- Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. *Nat Rev Cardiol* 2016; 13: 48–60.
- Dmitrieva VG, Savushkin EV, Zuikova EB, Nosova EV, Litvinov DY, Dergunov AD et al. Key Human Blood Cells Genes Involved in Atherogenesis and Metabolism of High Density Lipoproteins. *Molecular Genetics, Microbiology and Virology* 2018; 33: 84–90.
- Dergunov AD, Litvinov DY, Bazaeva EV, Dmitrieva VG, Nosova EV, Rozhkova AV et al. Relation of High-Density Lipoprotein Charge Heterogeneity, Cholesterol Efflux Capacity, and the Expression of High-Density Lipoprotein-Related Genes in Mononuclear Cells to the HDL-Cholesterol Level. *Lipids* 2018; 53: 979–91.
- Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019; 47: D607–D613.
- Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and sta-

- tistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res* 2002; 30: e36.
17. McDonald JH (2015) Multiple comparisons. *Handbook of Biological Statistics*. <http://www.biostathandbook.com/multiplecomparisons> [3rd ed.], 254–260. Baltimore, Maryland, Sparky House Publishing.
 18. Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. *Curr Opin Lipidol* 2006; 17: 258–67.
 19. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. *J Biol Chem* 2004; 279: 9930–6.
 20. Nakamura Y, Kotite L, Gan Y, Spencer TA, Fielding CJ, Fielding PE. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. *Biochemistry* 2004; 43: 14811–20.
 21. Fielding PE, Kawano M, Catapano AL, Zoppo A, Marcovina S, Fielding CJ. Unique epitope of apolipoprotein A-I expressed in pre-beta-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. *Biochemistry* 1994; 33: 6981–5.
 22. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. *Biochemistry* 2007; 46: 8445–50.
 23. Aseem O, Smith BT, Cooley MA, Wilkerson BA, Argraves KM, Remaley AT et al. Cubilin maintains blood levels of HDL and albumin. *J Am Soc Nephrol* 2014; 25: 1028–36.
 24. Hammad SM, Barth JL, Knaak C, Argraves WS. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. *J Biol Chem* 2000; 275: 12003–8.
 25. Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. *Nat Med* 1999; 5: 656–61.
 26. Marcil M, Yu L, Krimbou L, Boucher B, Oram JF, Cohn JS et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. *Arterioscler Thromb Vasc Biol* 1999; 19: 159–69.
 27. Chiu DS, Oram JF, LeBoeuf RC, Alpers CE, O'Brien KD. High-density lipoprotein-binding protein (HBP)/vigilin is expressed in human atherosclerotic lesions and colocalizes with apolipoprotein E. *Arterioscler Thromb Vasc Biol* 1997; 17: 2350–8.
 28. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. *J Mol Med (Berl)* 2006; 84: 276–94.
 29. Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. *J Lipid Res* 2007; 48: 592–9.
 30. Gent J, Braakman I. Low-density lipoprotein receptor structure and folding. *Cell Mol Life Sci* 2004; 61: 2461–70.
 31. Haidar B, Denis M, Krimbou L, Marcil M, Genest J, Jr. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. *J Lipid Res* 2002; 43: 2087–94.
 32. Haidar B, Denis M, Marcil M, Krimbou L, Genest J, Jr. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. *J Biol Chem* 2004; 279: 9963–9.
 33. Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Arstikaitis P et al. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. *Circ Res* 2009; 105: 138–47.
 34. Ganjali S, Gotto AM, Jr, Ruscica M, Atkin SL, Butler AE, Banach M et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. *J Cell Physiol* 2018; 233: 9237–46.
 35. Boraschi D, Dinarello CA. IL-18 in autoimmunity: review. *Eur Cytokine Netw* 2006; 17: 224–52.
 36. Ossoli A, Remaley AT, Vaisman B, Calabresi L, Gomaschi M. Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes. *Biochem J* 2016; 473: 211–9.
 37. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Storzaker RA, McCormick SP et al. High-density lipoprotein reduces the human monocyte inflammatory response. *Arterioscler Thromb Vasc Biol* 2008; 28: 2071–7.
 38. McManus DD, Rong J, Huan T, Lacey S, Tanriverdi K, Munson PJ et al. Messenger RNA and MicroRNA transcriptomic signatures of cardiometabolic risk factors. *BMC Genomics* 2017; 18: 139.

Received: September 17, 2019

Accepted: October 20, 2019